Viatris
VTRS Nasdaq· Pharmaceuticals
Last close · Oct 26, 2026
$18.29
KIRA · Stoqly’s AI analyst, in plain words
- Viatris had $14.3B of revenue in fiscal 2025, down 3.0% on the year before. Over five years, revenue changed +3.7% a year on average.
- Its operating margin was −18.6%, down 18.7 pts: of every 100 in sales, about −19 is left after running the business.
- Viatris lost $3.5B in fiscal 2025.
- Free cash flow was $1.9B in fiscal 2025, 13.6% of revenue.
- Viatris returned $501M to shareholders in fiscal 2025, 26% of free cash flow. The diluted share count fell 1.9%.
- Viatris owes $13.1B more than it holds in cash, about 96.5 years of operating profit.
Market cap
$21.3B
P/E
—
Revenue
$14.3B
Net income
−$3.5B
Free cash flow
$1.9B
Operating margin
−18.6%
Viatris in 30 seconds · fiscal 2025
Are sales growing?
−3.0%
No. Sales fell 3.0% last year.
Does it make a profit?
−24.6%
No. It lost money last year.
Does profit turn into cash?
13.6%
Yes. 13.6% of sales ends up as free cash.
Is debt under control?
96.5x
Heavy. Repaying its debt would take 96.5 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
What Viatris does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- VIATRIS INC.
- CIK
- 0001792044
Viatris · VTRS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Revenue growth | 49.7% | −9.1% | −5.1% | −4.5% | −3.0% |
| Gross margin | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% |
| Operating margin | −0.2% | 9.9% | 5.0% | 0.1% | −18.6% |
| Net income | −$1.3B | $2.1B | $54.7M | −$634M | −$3.5B |
| Net margin | −7.1% | 12.8% | 0.4% | −4.3% | −24.6% |
| Diluted EPS | −$1.05 | $1.71 | $0.05 | −$0.53 | −$3.00 |
| Cash | |||||
| Cash from operations | $3.0B | $3.0B | $2.9B | $2.3B | $2.3B |
| Capital expenditure | $457M | $406M | $377M | $326M | $379M |
| Free cash flow | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| FCF margin | 14.3% | 15.9% | 16.4% | 13.4% | 13.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $250M | $250M | $501M |
| Share count change | 101.1% | 0.7% | −0.9% | −1.1% | −1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $739M | $1.3B | $1.0B | $773M | $1.4B |
| Debt incl. finance leases | $23.1B | $19.3B | $18.1B | $14.0B | $14.4B |
| Shareholders' equity | $20.5B | $21.1B | $20.5B | $18.6B | $14.7B |
| Net debt / EBITDA | 5.0x | 3.9x | 4.9x | 4.6x | 96.5x |
| Current ratio | 1.1x | 1.6x | 1.7x | 1.7x | 1.4x |
| Interest coverage | −0.1x | 2.7x | 1.3x | 0.0x | −5.7x |
| Returns and quality | |||||
| Return on capital | −0.1% | 2.9% | 1.0% | 0.0% | −7.1% |
| Return on equity | −5.8% | 10.0% | 0.3% | −3.2% | −21.1% |
| Piotroski F-score | 4 | 8 | 7 | 5 | 4 |
| Altman Z'' | 1.0 | 1.8 | 1.9 | 1.7 | 0.7 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$1.1M
1 insider
Of sales under plans
74%
$0.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Viatris · VTRS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Viatris VTRS | $21.3B | −3.0% | −18.6% | 13.6% | −7.1% | — | 4 |
| Teva Pharmaceuticals TEVA | $46.5B | 4.3% | 12.5% | 6.7% | 10.5% | 66.6x | 8 |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | — | 7 |
| Zoetis ZTS | $33.8B | 2.3% | — | 24.1% | 29.3% | 13.3x | 8 |
| Elanco ELAN | $11.6B | 6.2% | — | 6.0% | −0.1% | — | 6 |
KIRA
At $18.29 a share, the company is worth $21.3B.
Viatris grew sales faster than 0 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001792044). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.